Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sunitinib maleate intravitreal - CalciMedica

Next Previous
Drug Profile

Sunitinib maleate intravitreal - CalciMedica

Alternative Names: GB 102- CalciMedica; GB 103- CalciMedica; Intravitreal sunitinib maleate - CalciMedica

Latest Information Update: 22 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GrayBug inc.
  • Developer CalciMedica
  • Class Amides; Antineoplastics; Ethylamines; Eye disorder therapies; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Colony stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 20 Mar 2023 GrayBug inc. has merged with CalciMedica to form CalciMedica
  • 11 Aug 2022 Suspended - Phase-II for Diabetic macular oedema (Treatment-experienced) in USA due to cost-containment measures (Intravitreous)
  • 11 Aug 2022 Suspended - Phase-II for Retinal vein occlusion (Treatment-experienced) in USA due to cost-containment measures (Intravitreous)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top